Search

Pharming Group NV

Fermé

0.717 -2.45

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.71

Max

0.739

Chiffres clés

By Trading Economics

Revenu

259K

-959K

Ventes

756K

75M

BPA

0.005

Marge bénéficiaire

-1.281

EBITDA

1.9M

Dividendes

By Dow Jones

Prochains Résultats

8 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

534M

Ouverture précédente

3.17

Clôture précédente

0.717

Pharming Group NV Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 avr. 2025, 23:04 UTC

Actualités

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 avr. 2025, 22:40 UTC

Principaux Mouvements du Marché

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 avr. 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 avr. 2025, 18:51 UTC

Acquisitions, Fusions, Rachats

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 avr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 avr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 avr. 2025, 22:22 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 22:21 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 21:43 UTC

Actualités
Résultats

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 avr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 avr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 avr. 2025, 20:34 UTC

Actualités

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 avr. 2025, 20:23 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 20:15 UTC

Acquisitions, Fusions, Rachats

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 avr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 avr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 avr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 avr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 avr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 avr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 avr. 2025, 18:38 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 18:30 UTC

Actualités

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 avr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 avr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 avr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 avr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Pharming Group NV prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.